-
2
-
-
0027996196
-
-
(a) Bella, J.; Eaton, M.; Brodsky, B.; Berman, H. M. Science 1994, 266, 75-81.
-
(1994)
Science
, vol.266
, pp. 75-81
-
-
Bella, J.1
Eaton, M.2
Brodsky, B.3
Berman, H.M.4
-
3
-
-
0036147722
-
-
(b) Berisio, R.; Vitagliano, L.; Mazzarella, L.; Zagari, A. Protein Sci. 2002, 11, 262-270.
-
(2002)
Protein Sci
, vol.11
, pp. 262-270
-
-
Berisio, R.1
Vitagliano, L.2
Mazzarella, L.3
Zagari, A.4
-
4
-
-
33847639117
-
-
Hyp = 4(R)-hydroxy-L-proline.
-
(c) Hyp = 4(R)-hydroxy-L-proline.
-
-
-
-
7
-
-
20444431568
-
-
(b) Penz, S.; Reininger, A. J.; Brandl, R.; Goyal, P.; Rabie, T.; Bernlochner, I.; Rother, E.; Goetz, C.; Engelman, B.; Smethurst, P. A.; Ouwehand, W. H.; Farndale, R.; Nieswandt, B.; Siess, W. FASEB J. 2005, 19, 898-909.
-
(2005)
FASEB J
, vol.19
, pp. 898-909
-
-
Penz, S.1
Reininger, A.J.2
Brandl, R.3
Goyal, P.4
Rabie, T.5
Bernlochner, I.6
Rother, E.7
Goetz, C.8
Engelman, B.9
Smethurst, P.A.10
Ouwehand, W.H.11
Farndale, R.12
Nieswandt, B.13
Siess, W.14
-
8
-
-
0029837626
-
-
(a) Feng, Y.; Melacini, G.; Taulane, J. P.; Goodman, M. J. Am. Chem. Soc. 1996, 118, 10351-10358.
-
(1996)
J. Am. Chem. Soc
, vol.118
, pp. 10351-10358
-
-
Feng, Y.1
Melacini, G.2
Taulane, J.P.3
Goodman, M.4
-
9
-
-
0029782362
-
-
and references therein
-
(b) Fields, G. B.; Prockop, D. J. Biopolymers 1996, 40, 345-357 and references therein.
-
(1996)
Biopolymers
, vol.40
, pp. 345-357
-
-
Fields, G.B.1
Prockop, D.J.2
-
10
-
-
0032537113
-
-
(c) Holmgren, S. K.; Taylor, K. M.; Bretscher, L. E.; Raines, R. T. Nature 1998, 592, 666-667.
-
(1998)
Nature
, vol.592
, pp. 666-667
-
-
Holmgren, S.K.1
Taylor, K.M.2
Bretscher, L.E.3
Raines, R.T.4
-
12
-
-
0029794908
-
-
(e) Shah, N. K.; Ramshaw, J. A. M.; Kirkpatrick, A.; Shah, C.; Brodsky, B. Biochemistry 1996, 35, 10262-10268.
-
(1996)
Biochemistry
, vol.35
, pp. 10262-10268
-
-
Shah, N.K.1
Ramshaw, J.A.M.2
Kirkpatrick, A.3
Shah, C.4
Brodsky, B.5
-
13
-
-
0028227278
-
-
(a) Rao, G. H. R.; Fields, C. G.; White, J. G.; Fields, G. B. J. Biol. Chem. 1994, 269, 13899-13903.
-
(1994)
J. Biol. Chem
, vol.269
, pp. 13899-13903
-
-
Rao, G.H.R.1
Fields, C.G.2
White, J.G.3
Fields, G.B.4
-
14
-
-
0028986390
-
-
(b) Morton, L. F.; Hargreaves, P. G.; Farndale, R. W.; Young, R. D.; Barnes, M. J. Biochem. J. 1995, 306, 337-344.
-
(1995)
Biochem. J
, vol.306
, pp. 337-344
-
-
Morton, L.F.1
Hargreaves, P.G.2
Farndale, R.W.3
Young, R.D.4
Barnes, M.J.5
-
15
-
-
0033019112
-
-
(c) Knight, C. G.; Morton, L. F.; Onley, D. J.; Peachey, A. R.; Ichinohe, T.; Okuma, M.; Farndale, R. W.; Barnes, M. J. Cardiovasc. Res. 1999, 41, 450-457.
-
(1999)
Cardiovasc. Res
, vol.41
, pp. 450-457
-
-
Knight, C.G.1
Morton, L.F.2
Onley, D.J.3
Peachey, A.R.4
Ichinohe, T.5
Okuma, M.6
Farndale, R.W.7
Barnes, M.J.8
-
16
-
-
26844568706
-
-
(a) Koide, T.; Homma, D. L.; Asada, S.; Kitagawa, K. Bioorg. Med. Chem. Lett. 2005, 15, 5230-5233.
-
(2005)
Bioorg. Med. Chem. Lett
, vol.15
, pp. 5230-5233
-
-
Koide, T.1
Homma, D.L.2
Asada, S.3
Kitagawa, K.4
-
20
-
-
0041785390
-
-
Gdaniec M.; Jankowski, W.; Milewska, M. J.; Poloñski, T. Angew. Chem., Int. Ed. 2003, 42, 3903-3906 (also, ref 9 and 10 cited therein).
-
(b) Gdaniec M.; Jankowski, W.; Milewska, M. J.; Poloñski, T. Angew. Chem., Int. Ed. 2003, 42, 3903-3906 (also, ref 9 and 10 cited therein).
-
-
-
-
21
-
-
0034741388
-
-
(c) Lozman, O. R.; Bushby, R. J.; Vinter, J. G. J. Chem. Soc., Perkin Tran. 2001, 2, 1446-1453.
-
(2001)
J. Chem. Soc., Perkin Tran
, vol.2
, pp. 1446-1453
-
-
Lozman, O.R.1
Bushby, R.J.2
Vinter, J.G.3
-
22
-
-
33847613707
-
-
For details. see the Supporting Information
-
For details. see the Supporting Information.
-
-
-
-
23
-
-
33847643488
-
-
If the aromatic rings were placed in an edge-to-face orientation, the reminimized assembly reverted to the face-to-face orientation
-
If the aromatic rings were placed in an edge-to-face orientation, the reminimized assembly reverted to the face-to-face orientation.
-
-
-
-
24
-
-
33847659422
-
-
Peptide 2b did not induce platelet aggregation under various conditions.
-
Peptide 2b did not induce platelet aggregation under various conditions.
-
-
-
-
26
-
-
33847622312
-
-
The integrin GPIIb/IIIa, which is activated at the final stage of platelet aggregation, responds to various agonists, including collagen
-
(b) The integrin GPIIb/IIIa, which is activated at the final stage of platelet aggregation, responds to various agonists, including collagen.
-
-
-
|